Healthcare - Biotechnology - NASDAQ - US
$ 9.49
-3.16 %
$ 462 M
Market Cap
-2.74
P/E
CASH FLOW STATEMENT
-89.2 M
OPERATING CASH FLOW
-84.7 M
INVESTING CASH FLOW
151 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
KalVista Pharmaceuticals, Inc.
| Net Income | -127 M |
| Depreciation & Amortization | 816 K |
| Capital Expenditures | -443 K |
| Stock-Based Compensation | 21.9 M |
| Change in Working Capital | 15.2 M |
| Others | 2.19 M |
| Free Cash Flow | -89.7 M |
Cash Flow
Millions
| Apr-2024 | Apr-2023 | Apr-2022 | Apr-2021 | Apr-2020 | Apr-2019 | Apr-2018 | Apr-2017 | Apr-2016 | Apr-2015 | Dec-2013 | Dec-2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||
| Net Income | (126.6) | (92.9) | (82.3) | (46.2) | (29.1) | (20.8) | (15.8) | (18.6) | (11.4) | (7.2) | (5.7) | (2.1) |
| Depreciation & Amortization | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.4 | 0.2 | 40 K | 33 K | 38 K | 27 K | 38 K |
| Deferred Income Tax | 0 | (0.5) | 0 | 42 K | 33 K | 0 | 0 | 0 | 0 | 0 | 63 K | 6 K |
| Stock Based Compensation | 21.9 | 9.9 | 11.1 | 7.1 | 4.4 | 3.0 | 1.1 | 0.4 | 0.1 | 36 K | 0.2 | 47 K |
| Other Operating Activities | (0.5) | 84 K | 4.9 | 0.1 | 13 K | (0.1) | (0.7) | (1.4) | (1.7) | 167 | 32 K | 0.1 |
| Change in Working Capital | 15.2 | 7.4 | (12.3) | 8.3 | (20.6) | (18.8) | 25.8 | (4.2) | (0.2) | 0.8 | 0.5 | 35 K |
| Cash From Operations | (89.2) | (75.3) | (78.1) | (30.2) | (44.8) | (36.4) | 10.6 | (23.7) | (13.2) | (6.4) | (4.9) | (1.8) |
| INVESTING CASH FLOW | ||||||||||||
| Capital Expenditures | (0.4) | (1.2) | (0.9) | 82 K | (0.2) | (1.1) | (1.4) | 74 K | 11 K | (0.1) | 18 K | 91 K |
| Other Items | (84.3) | 42.6 | 58.8 | (147.6) | 17.0 | (68.3) | 0 | 34.1 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (84.7) | 41.4 | 57.9 | (147.7) | 16.8 | (69.4) | (1.4) | 34.1 | 11 K | (0.1) | 18 K | 91 K |
| FINANCING CASH FLOW | ||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 54 K | (0.2) | (0.2) | 0 | 0 | 0 | 0.4 | (0.4) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 53.8 | 1.5 | 1.6 | 1.5 | 0.2 | 0.2 | 0 | 2 K | 66.0 | 17.3 | 6.0 | 6.0 |
| Cash From Financing Activities | 150.7 | 58.1 | 1.6 | 212.1 | 11.6 | 87.9 | 9.0 | 2 K | 33.0 | 8.7 | 6.4 | 5.6 |
| CHANGE IN CASH | ||||||||||||
| Net Change In Cash | (24.4) | 25.5 | (19.9) | 34.8 | (16.2) | (19.0) | 20.1 | 9.2 | 19.2 | 2.0 | 1.5 | 3.6 |
| FREE CASH FLOW | ||||||||||||
| Free Cash Flow | (89.7) | (76.5) | (79.1) | (30.3) | (45.0) | (37.4) | 9.1 | (23.8) | (13.2) | (6.5) | (4.9) | (1.9) |